Case study: Metformin-associated lactic acidosis. Could orlistat be relevant? [4]

Diabetes Care

Volumn 26, Issue 8, 2003, Pages 2471-2472

  Dawson, Dana ^a,c   Conlon, Christopher ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CREATININE; CYCLOSPORIN; METFORMIN; PHENFORMIN; PLACEBO; TETRAHYDROLIPSTATIN; UREA;

ABDOMINAL PAIN; ADULT; ANAMNESIS; CASE REPORT; CATHETERIZATION; CHRONIC DIARRHEA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG POTENTIATION; DUODENUM ULCER; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL SYMPTOM; GLASGOW COMA SCALE; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LETTER; METABOLIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; SHOCK; TREATMENT INDICATION; TREATMENT OUTCOME;

ACIDOSIS, LACTIC; ANTI-OBESITY AGENTS; ANTI-ULCER AGENTS; CIMETIDINE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; METFORMIN; MIDDLE AGED;

EID: 0041522701     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.8.2471     Document Type: Letter

References (14)

1. Davidson MB, Peters AL: An overview of metformin in the treatment of type 2 diabetes mellitus (Review Article). Am J Med 102:99-110, 1997
2. Chan NN, Brain HP, Feher MD: Metformin-associated lactic acidosis: a rare or very rare clinical entity (Review Article) Diabet Med 16:273-281, 1999
3. Lalau JD, Race JM: Lactic acidosis in metformin therapy. Drugs 58 (Suppl. 1):55-60, 1999
4. Bailey CJ, Wilcock C, Day C: Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 105:1009-1013, 1992
5. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F: Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545-551, 1987
6. Sulkin TV, Bosman D, Krentz AJ: Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 20:925-928, 1997
7. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, Chauveau P, Dulbecco P, Guerin C, Haegy JM: Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18:779-784, 1995
8. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet 352:167-172, 1998
9. Zhi J, Moore R, Kanitra L, Mulligan TE: Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 42:1011-1019, 2002
10. Torgerson JS, Arlinger K, Kappi M, Sjostrom L: Principles for enhanced recruitment of subjects in a large clinical trial: the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. Control Clin Trials 22:515-525, 2001
11. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S: Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25:1123-1128, 2002
12. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P: Clinical efficacy of orlistat therapy in over-weight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 25:1033-1041, 2002
13. Lalau JD, Race JM, Brinquin L: Lactic acidosis in metformin therapy: relationship between plasma metformin concentration and renal function (Letter). Diabetes Care 21:1366-1367, 1998
14. Lalau JD, Race JM, Andreelli F, Lacroix C, Canarelli JP: Metformin retention independent of renal failure in intestinal occlusion. Diabetes Metab 27:24-28, 2001